Aaron Seth Kesselheim

Aaron Seth Kesselheim, MD, JD, MPH

Professor of Medicine
Member, HMS Center for Bioethics

Aaron S. Kesselheim, MD, JD, MPH, is a Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital. Within the Division, Aaron created and leads the Program On Regulation, Therapeutics, And Law (PORTAL, www.PORTALresearch.org), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. PORTAL is now among the largest, independent academic centers focusing on these issues in the country (Twitter: @PORTAL_research, @akesselheim). Dr. Kesselheim received his medical and legal training at the University of Pennsylvania and his M.P.H. at the Harvard School of Public Health. Author of over 450 publications in the peer-reviewed medical and health policy literatures, Aaron has testified before Congress on pharmaceutical policy, medical device regulation, generic drugs, and modernizing clinical trials, is a member of the FDA Peripheral and Central Nervous System Advisory Committee, and served on a National Academies of Science, Engineering and Medicine consensus committees on addressing the opioid epidemic and bioidentical hormone replacement. At the HMS Center for Bioethics, he co-teaches a course on health policy, law, and bioethics and organizes the monthly policy and ethics consortium.

Publications View
A matter of trust: patient barriers to primary medication adherence.
Authors: Authors: Polinski JM, Kesselheim AS, Frolkis JP, Wescott P, Allen-Coleman C, Fischer MA.
Health Educ Res
View full abstract on Pubmed
Association of medical students' reports of interactions with the pharmaceutical and medical device industries and medical school policies and characteristics: a cross-sectional study.
Authors: Authors: Yeh JS, Austad KE, Franklin JM, Chimonas S, Campbell EG, Avorn J, Kesselheim AS.
PLoS Med
View full abstract on Pubmed
Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugs.
Authors: Authors: Kesselheim AS, Tan YT, Darrow JJ, Avorn J.
Health Aff (Millwood)
View full abstract on Pubmed
Electronic medication packaging devices and medication adherence: a systematic review.
Authors: Authors: Checchi KD, Huybrechts KF, Avorn J, Kesselheim AS.
JAMA
View full abstract on Pubmed
Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.
Authors: Authors: Gagne JJ, Choudhry NK, Kesselheim AS, Polinski JM, Hutchins D, Matlin OS, Brennan TA, Avorn J, Shrank WH.
Ann Intern Med
View full abstract on Pubmed
Regulating incremental innovation in medical devices.
Authors: Authors: Kesselheim AS, Rajan PV.
BMJ
View full abstract on Pubmed
The Food and Drug Administration's role in promoting consistent labels for generic drugs.
Authors: Authors: Duke JD, Kesselheim AS.
JAMA Intern Med
View full abstract on Pubmed
Life cycle of medical product rules issued by the US Food and Drug Administration.
Authors: Authors: Hwang TJ, Avorn J, Kesselheim AS.
J Health Polit Policy Law
View full abstract on Pubmed
Association of marketing interactions with medical trainees' knowledge about evidence-based prescribing: results from a national survey.
Authors: Authors: Austad KE, Avorn J, Franklin JM, Campbell EG, Kesselheim AS.
JAMA Intern Med
View full abstract on Pubmed
Introduction to a supplement on innovative approaches to studying health outcomes in rare diseases.
Authors: Authors: Kesselheim AS, Gagne JJ.
J Gen Intern Med
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
Boston, MA 02120